Results 41 to 50 of about 2,399 (178)
Pharmacoepidemiology and Drug Safety, Volume 35, Issue 4, April 2026.ABSTRACT Background Studies comparing treatment strategies based on initiation timing—such as starting PCSK9 inhibitor (PCSK9i) therapy sooner versus later after a myocardial infarction (MI)—are prone to immortal time bias. Clone‐censor‐weight methods can address these issues and allow the researcher to emulate a trial in which patients are assigned to
Thomas Cars +13 more
wiley +1 more source
Clinical Case Reports, 2019 We successfully treated a patient with homozygous familial hypercholesterolemia (HoFH) with stable coronary arterial disease using optimal medical therapy and low‐density lipoprotein (LDL) apheresis for 16 years without percutaneous coronary intervention
Takanori Yasu +6 more
doaj +1 more source
Transfusion, Volume 66, Issue 4, Page 689-699, April 2026.Abstract Background Blood administration sets are changed after a prescribed time interval with variations in guidelines. In Canada, sets are changed every 4 h based on the theory of potential bacterial attachment. This study aimed to investigate whether bacteria adhere to the inner surfaces of blood administration sets during mimicked transfusions of ...
Zoya Versey +4 more
wiley +1 more source
Turkish Journal of Hematology, 2012 OBJECTIVE: The aim of our study is to discuss the efficacy of low-density lipoprotein-cholesterol (LDL-C) apheresis procedure using the cascade filtration system for pediatric patients with homozygous familial hypercholesterolemia (FH), and to clarify ...
Fatih Kardas +7 more
doaj +1 more source
Is LDL apheresis a thing of the past?
South African General Practitioner, 2020 Patients with severe hypercholesterolaemia have a high lifetime risk for developing cardiovascular disease. These patients are traditionally treated with high-intensity statins and ezetimibe. Some patients are refractory to treatment and cannot achieve a desirable reduction in low-density lipoprotein cholesterol (LDL-C).
M Vally, R Khan, A Orchard
openaire +2 more sources
Spectrum of cardiovascular manifestations in homozygous familial hypercholesterolemia
Journal of Marine Medical Society, 2023 Homozygous familial hypercholesterolemia (HoFH) is a rare, primarily an autosomal dominant genetic disorder that causes markedly elevated low-density lipoprotein (LDL) cholesterol levels predisposing patients to risk of developing premature ...
Nitin Bajaj +3 more
doaj +1 more source
Extracorporeal LDL-Cholesterol Elimination in the Treatment of Severe Familial Hypercholesterolemia
Acta Medica, 2003 The extracorporeal elimination of LDL-cholesterol could be performed using the classic non-selective centrifuge or membrane plasmapheresis. The modern methods are more selective and effective.
Milan Bláha
doaj +1 more source
Recent Progress in Double Filtration Plasmapheresis
Hemodialysis International, Volume 30, Issue 1, Page 18-25, January 2026.ABSTRACT Double‐filtration plasmapheresis is an advanced extracorporeal blood purification technique that selectively removes pathogenic macromolecules based on molecular weight. Unlike conventional plasma exchange, double‐filtration plasmapheresis uses a two‐step filtration process to retain beneficial plasma components such as albumin, while ...
Dan Li +3 more
wiley +1 more source
Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia
Lipids in Health and Disease, 2011 Background Myeloperoxidase (MPO) is a marker of plaque vulnerability and a mechanistic bridge between inflammation and cardiovascular disease, and thus is a suitable target for therapeutic strategy against cardiovascular disease.
Minichilli Fabrizio +5 more
doaj +1 more source
JACC: Case Reports, 2019 This case report describes a 50-year-old-woman from Southeast Asia with extensive atherosclerotic cardiovascular disease, found to have homozygous familial hypercholesterolemia caused by variants of uncertain significance in both the APOB and LDLR genes.
Robert Derenbecker, MD +7 more
doaj +1 more source